MiNK's agenT-797 Selected for $87M ARPA-H Room-Temperature Cell Therapy Program
INKT sits 88% above its 52-week low of $8.48 on elevated volume (1.8× avg).
Summary
MiNK's clinical-stage agenT-797 iNKT platform has been selected as a therapeutic cell system within an ARPA-H-funded team developing room-temperature storage for cell therapies. The four-year BoSS program has up to $87 million committed across the initiative, with MiNK as a core member of the RAB team led by Draper. This validates the platform's deployability and could expand access beyond specialized centers. The company has a going concern warning and relies on dilutive ATM offerings, so non-dilutive government funding is a meaningful positive. Watch for further details on MiNK's specific funding allocation and milestones.
At the time of this announcement, INKT was trading at $15.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $62.6M. The 52-week trading range was $8.48 to $16.93. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.